Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
BEIJING INNOCARE PHARMA TECH CO., LTD. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and the distinct art units. This distribution shows that each pending matter is being handled by a separate examiner in a separate administrative division. Liu, Tracy is the busiest examiner for the portfolio with 1 pending office action.
With the distinct examiners each holding a pending office action, the workload is divided. This requires the company to address different sets of examiner expectations across the 2 distinct art units. The presence of the pending office actions within the Biotechnology & Pharmaceuticals area indicates a focused but administratively diverse prosecution effort. Practitioners should tailor their approach to the specific requirements of both the art units and the examiners involved in these cases. The 1 pending office action under Liu, Tracy is a key part of this process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIU, TRACY | 1 | 54.5% | +26.9% |
| KUCKLA, ANNA GRACE | 1 | 53.8% | +51.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18646464 | AMORPHOUS SOLID DISPERSION COMPRISING (S)-1-(1-ACRYLOYLPYRROLIDIN-3-YL)-3-((3,5-DIMETHOXYPHENYL)ETHYNYL)-5-(METHYLAMINO)-1H-PYRAZOLE-4-CARBOXAMIDE | LIU, TRACY | 62d |
| 18014623 | HETEROCYCLIC IMMUNOMODULATOR | KUCKLA, ANNA GRACE | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18646464 | AMORPHOUS SOLID DISPERSION COMPRISING (S)-1-(1-ACRYLOYLPYRROLIDIN-3-YL)-3-((3,5-DIMETHOXYPHENYL)ETHYNYL)-5-(METHYLAMINO)-1H-PYRAZOLE-4-CARBOXAMIDE | LIU, TRACY | 1614 | §103 | Non-Final OA | 62d | Pending | Apr 25, 2024 |
| 18014623 | HETEROCYCLIC IMMUNOMODULATOR | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBEIJING INNOCARE PHARMA TECH CO., LTD. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Tracy Liu has the most, with 1 of BEIJING INNOCARE PHARMA TECH CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
